Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Clinical trial NCT05455697 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05455697
- Sponsor
- University of Washington
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-26
- Primary completion
- 2026-10-15
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.